Research Report
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 7, 2014; 20(33): 11780-11787
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11780
Table 1 Immunohistochemistry protocols used to characterize the proteins expression
CodeIndustryDilutionEpitope retrievalAmplification system
MCT1 (sc-365501)Santa Cruz Biotechnology, Santa Cruz, CA, United States1:500EDTA (1 mmol/L, pH = 8);Vectastain® Elite ABC reagent
98 °C; 20 min(Burlingame, CA, United States)
MCT2 (sc-14926)Santa Cruz Biotechnology, Santa Cruz, CA, United States1:200Citrate buffer (10 mmol/L, pH = 6); 98 °C; 20 minUltravision Detection System Anti-polyvalent, HRP, Lab Vision Corporation, Fremont, CA, United States)
MCT4 (sc-50329)Santa Cruz Biotechnology, Santa Cruz, CA, United States1:500Citrate buffer (10 mmol/L, pH = 6); 98 °C; 20 minUltravision Detection System Anti-polyvalent, HRP, Lab Vision Corporation, Fremont, CA, United States)
CD147 (sc-71038)Santa Cruz Biotechnology, Santa Cruz, CA, United States1:400EDTA (1 mmol/L, pH = 8);Vectastain® Elite ABC reagent (Burlingame, CA, United States)
98 °C; 20 min
GLUT1 (ab15309)Abcam, Cambridge, United Kingdom1:500Citrate buffer (10 mmol/L, pH = 6); 98 °C; 20 minUltravision Detection System Anti-polyvalent, HRP, Lab Vision Corporation, Fremont, CA, United States)
Caspase 3Diagnostic BioSystems (DBS) Pleasanton, CA, United States1:160Citrate buffer (10 mmol/L, pH = 6); 98 °C; 40 minNovoLink (Novocastra Laboratories Ltd, Newcastle Upon Tyne, United Kingdom)
(3C SP03)
Keratin 19 (K19, b170)Novocastra Laboratories Ltd, Newcastle Upon Tyne, United Kingdom1:300Citrate buffer (10 mmol/L, pH = 6); 98 °C; 40 minNovoLink (Novocastra Laboratories Ltd, Newcastle Upon Tyne, United Kingdom)
Ki-67 (MIB-1)(Dako, Glostrup, Denmark)1:400Citrate buffer (10 mmol/L, pH = 6); 98 °C; 40 minNovoLink (Novocastra Laboratories Ltd, Newcastle Upon Tyne, United Kingdom)
EGFR human (DAK-H1-WT)(Dako, Glostrup, Denmark)1:200Citrate buffer (10 mmol/L, pH = 6); 98 °C; 40 minNovoLink (Novocastra Laboratories Ltd, Newcastle Upon Tyne, United Kingdom)
Table 2 Association of overall expression of cell metabolism markers with the neoplastic (including metastasis) and non-neoplastic status of the liver n (%)
MCT1
MCT2
MCT4
CD147
GLUT1
nPositiveP valuenPositiveP valuenPositiveP valuenPositiveP valuenPositiveP value
Non-neoplastic2625 (96.2)2623 (88.5)263 (11.5)2622 (84.6)260 (0.0)
Primary tumor7346 (63.0)7452 (70.3)7631 (40.8)7536 (48.0)767 (9.2)
Metastasis169 (56.2)166 (46.2)1711 (64.7)1710 (58.8)175 (29.4)
0.0030.020.0010.0050.007
Table 3 Association of the plasma membrane expression of cell metabolism markers with the neoplastic (including metastasis) and non-neoplastic status of the liver n (%)
MCT1
MCT2
MCT4
CD147
GLUT1
nPositiveP valuenPositiveP valuenPositiveP valuenPositiveP valuenPositiveP value
Non-neoplastic2625 (96.2)260 (0.0)261 (3.8)2620 (76.9)260 (0.0)
Primary tumor7340 (54.8)749 (12.2)7629 (38.2)7532 (42.7)764 (5.3)
Metastasis169 (56.2)161 (7.7)178 (47.1)179 (52.9)173 (17.6)
0.0010.1690.0020.0110.052
Table 4 Association of the plasma membrane expression of monocarboxylate transporters with the plasma membrane expression of the chaperone CD147 and the glycolytic protein glucose transporter 1 n (%)
CD147
GLUT1
nPositiveP valuenPositiveP value
MCT1< 0.0011.000
Negative404 (10.0)402 (5.0)
Positive7456 (75.7)744 (5.4)
MCT20.7660.434
Negative10256 (54.9)1035 (4.9)
Positive105 (50.0)101 (10.0)
MCT40.1140.004
Negative8046 (57.5)811 (1.2)
Positive3615 (41.7)386 (15.8)